Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

David M. Ficker, M. Privitera, G. Krauss, Andres M Kanner, J. L. Moore, T. Glauser

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

Original languageEnglish (US)
Pages (from-to)593-595
Number of pages3
JournalNeurology
Volume65
Issue number4
DOIs
StatePublished - Aug 23 2005
Externally publishedYes

Fingerprint

Carbamazepine
Epilepsy
Capsules
Seizures
Quality of Life

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. / Ficker, David M.; Privitera, M.; Krauss, G.; Kanner, Andres M; Moore, J. L.; Glauser, T.

In: Neurology, Vol. 65, No. 4, 23.08.2005, p. 593-595.

Research output: Contribution to journalArticle

Ficker, David M. ; Privitera, M. ; Krauss, G. ; Kanner, Andres M ; Moore, J. L. ; Glauser, T. / Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. In: Neurology. 2005 ; Vol. 65, No. 4. pp. 593-595.
@article{eaca6fcdd6dd4a6285909deca95e0629,
title = "Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine",
abstract = "The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.",
author = "Ficker, {David M.} and M. Privitera and G. Krauss and Kanner, {Andres M} and Moore, {J. L.} and T. Glauser",
year = "2005",
month = "8",
day = "23",
doi = "10.1212/01.wnl.0000172932.95985.51",
language = "English (US)",
volume = "65",
pages = "593--595",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine

AU - Ficker, David M.

AU - Privitera, M.

AU - Krauss, G.

AU - Kanner, Andres M

AU - Moore, J. L.

AU - Glauser, T.

PY - 2005/8/23

Y1 - 2005/8/23

N2 - The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

AB - The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

UR - http://www.scopus.com/inward/record.url?scp=23844508153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844508153&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000172932.95985.51

DO - 10.1212/01.wnl.0000172932.95985.51

M3 - Article

C2 - 16116122

AN - SCOPUS:23844508153

VL - 65

SP - 593

EP - 595

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -